209 related articles for article (PubMed ID: 24020238)
1. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
[TBL] [Abstract][Full Text] [Related]
2. [New antiretroviral drug classes in HIV therapy].
Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
[No Abstract] [Full Text] [Related]
3. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
[TBL] [Abstract][Full Text] [Related]
5. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
[TBL] [Abstract][Full Text] [Related]
7. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
8. [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Moreno Cuerda VJ; Rubio García R; Barros Aguado C; Morales Conejo M
Rev Clin Esp; 2008 Oct; 208(9):463-6. PubMed ID: 19000475
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
[TBL] [Abstract][Full Text] [Related]
10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV agents. New drugs--hope and a degree of caution.
TreatmentUpdate; 2007; 19(6):9-10. PubMed ID: 18041153
[No Abstract] [Full Text] [Related]
13. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
15. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
Pau AK; Penzak SR; Boyd SD; McLaughlin M; Morse CG
Pharmacotherapy; 2012 Jan; 32(1):e1-6. PubMed ID: 22392831
[TBL] [Abstract][Full Text] [Related]
16. Two new drugs for HIV infection.
Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
[No Abstract] [Full Text] [Related]
17. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
[TBL] [Abstract][Full Text] [Related]
18. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]